RT Journal Article
T1 Alterations in Circulating Monocytes Predict COVID-19 Severity and Include Chromatin Modifications Still Detectable Six Months after Recovery
A1 Utrero Rico, Alberto
A1 González Cuadrado, Cecilia
A1 Chivite Lacaba, Marta
A1 Cabrera Marante, Óscar
A1 Laguna Goya, Rocío
A1 Almendro Vázquez, Patricia
A1 Díaz Pedroche, Carmen
A1 Ruiz Ruigómez, María
A1 Lalueza Blanco, Antonio
A1 Folgueira López, María Dolores
A1 Vázquez, Enrique
A1 Quintas, Ana
A1 Berges Buxeda, Marcos J.
A1 Martín Rodriguez, Moisés
A1 Dopazo, Ana
A1 Serrano Hernández, Antonio
A1 Aguado García, José María
A1 Paz Artal, Estela Natividad
AB An early analysis of circulating monocytes may be critical for predicting COVID-19 course and its sequelae. In 131 untreated, acute COVID-19 patients at emergency room arrival, monocytes showed decreased surface molecule expression, including low HLA-DR, in association with an inflammatory cytokine status and limited anti-SARS-CoV-2-specific T cell response. Most of these alterations had normalized in post-COVID-19 patients 6 months after discharge. Acute COVID-19 monocytes transcriptome showed upregulation of anti-inflammatory tissue repair genes such as BCL6, AREG and IL-10 and increased accessibility of chromatin. Some of these transcriptomic and epigenetic features still remained in post-COVID-19 monocytes. Importantly, a poorer expression of surface molecules and low IRF1 gene transcription in circulating monocytes at admission defined a COVID-19 patient group with impaired SARS-CoV-2-specific T cell response and increased risk of requiring intensive care or dying. An early analysis of monocytes may be useful for COVID-19 patient stratification and for designing innate immunity-focused therapies.
PB MDPI
SN 2227-9059
YR 2021
FD 2021-09-10
LK https://hdl.handle.net/20.500.14352/5048
UL https://hdl.handle.net/20.500.14352/5048
LA eng
NO Utrero Rico, A., González Cuadrado, C., Chivite Lacaba, M. et al. «Alterations in Circulating Monocytes Predict COVID-19 Severity and Include Chromatin Modifications Still Detectable Six Months after Recovery». Biomedicines, vol. 9, n.o 9, septiembre de 2021, p. 1253. DOI.org (Crossref), https://doi.org/10.3390/biomedicines9091253.
NO This study was supported by the Instituto de Salud Carlos III, Spanish Ministry of Science and Innovation (COVID-19 research call COV20/00181)—co-financed by the European Development Regional Fund “A way to achieve Europe” and by Consejería de Sanidad de la Comunidad de Madrid (CÍVICO study 2020/0082). R.L.G. and O.C.M. hold a research contract “Rio Hortega” (CM19/00120 and CM19/00092, respectively) from the Instituto de Salud Carlos III, Spanish Ministry of Science and Innovation. MCL holds a predoctoral fellowship (FPU19/06393) from the Spanish Ministry of Science and Innovation.
NO Unión Europea
NO Ministerio de Ciencia, Innovación y Universidades (España)
NO Comunidad de Madrid
NO Instituto de Salud Carlos III
DS Docta Complutense
RD 3 abr 2025